Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis
BackgroundTrastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that is effective in treating gastrointestinal (GI) cancers. However, the significant variability in its reported efficacy and safety profiles is likely due to differences in trial designs, patient populations, and clinical...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Frontiers Media S.A.
2025-04-01
|
| سلاسل: | Frontiers in Gastroenterology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.frontiersin.org/articles/10.3389/fgstr.2025.1559934/full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|